Indraprastha Medical Corporation share price & results
- Jun 2026
- Sept 2026
Operates Indraprastha Apollo Hospitals in Delhi (Sarita Vihar) and Noida, part of the Apollo Hospitals Group.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 406 | +11.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 20.0 | 0.0 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 56.0 | +9.8% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
| Return on equity | 28.10 | −2.6 pts | Trailing twelve months | TTM to Jun 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | 7.22 | −1.7 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | 10.92 | +0.5 pts | Trailing twelve months | TTM to Jun 2026 | Revenue change against the same period one year earlier. |
Price
Performance −42.7% 1Y
1Y: ₹544.4 on 24 Oct 2025 → ₹312.2. High ₹622.8 (6 Nov 2025), low ₹299.8 (23 Oct 2026).
- Previous close
- ₹299.95
- Market cap
- ₹2.8k Cr
- 52-week range
- ₹299.8 – ₹622.8
- One year
- −44.66%
- Price to earnings (TTM to Jun 2026)
- 14.63×
- Return on equity (TTM to Jun 2026)
- 28.10%
Overview
- Symbol
- NSE:INDRAMEDCO
- Sector
- Healthcare
- Exchange
- NSE
- Currency
- INR
What Indraprastha Medical Corporation Limited does
Based on the company's own presentations, annual report and earnings calls.
Indraprastha Medical Corporation Limited operates Indraprastha Apollo Hospitals, a multi-specialty hospital at Sarita Vihar on the Delhi-Mathura Road in New Delhi, and a second hospital in Noida, Uttar Pradesh. The company is affiliated with and operates under the Apollo Hospitals Group brand. It earns revenue by providing in-patient and out-patient medical treatment, along with associated diagnostics and pharmacy services, to patients at these hospital sites.
- Hospital locations
- 2 (Sarita Vihar, New Delhi; Noida, Uttar Pradesh)
- Network affiliation
- Operates under the Apollo Hospitals Group brand
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2021 to Mar 2026).
Financials
What the filings say
Net profit, year on year: +10% (quarter to jun 2026 against jun 2025).
| Line item | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 350 | 325 | 334 | 365 | 381 | 372 | 365 | 406 |
| Expenses | 286 | 273 | 272 | 292 | 310 | 310 | 304 | 326 |
| Operating profit | 64 | 52 | 61 | 73 | 71 | 62 | 61 | 80 |
| Operating margin | 18.0% | 16.0% | 18.0% | 20.0% | 19.0% | 17.0% | 17.0% | 20.0% |
| Other income | 6 | 5 | 6 | 7 | 7 | 7 | 7 | 8 |
| Interest | 2 | 2 | 1 | 2 | 2 | 1 | 1 | 2 |
| Depreciation | 11 | 11 | 11 | 10 | 11 | 11 | 11 | 12 |
| Profit before tax | 57 | 45 | 55 | 68 | 66 | 56 | 55 | 75 |
| Tax rate | 26.0% | 26.0% | 26.0% | 25.0% | 25.0% | 27.0% | 24.0% | 25.0% |
| Net profit | 42 | 33 | 41 | 51 | 49 | 41 | 42 | 56 |
| EPS (₹ per share) | 4.63 | 3.58 | 4.47 | 5.61 | 5.40 | 4.47 | 4.55 | 6.09 |
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 1,098 | 1,245 | 1,357 | 1,483 |
| Expenses | 948 | 1,051 | 1,112 | 1,216 |
| Operating profit | 151 | 192 | 244 | 267 |
| Other income | 10 | 17 | 22 | 28 |
| Interest | 4 | 5 | 7 | 6 |
| Depreciation | 40 | 40 | 44 | 43 |
| Profit before tax | 117 | 167 | 217 | 245 |
| Net profit | 86 | 123 | 161 | 183 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 92 | 92 | 92 | 92 | 92 | 92 |
| Reserves | 234 | 288 | 386 | 505 | 567 | 649 |
| Borrowings | 5 | 2 | 34 | 33 | 31 | 37 |
| Other liabilities | 131 | 173 | 212 | 222 | 264 | 214 |
| Total liabilities | 462 | 555 | 723 | 852 | 954 | 991 |
| Fixed assets | 277 | 275 | 347 | 328 | 351 | 365 |
| Capital work in progress | 0 | 3 | 0 | 33 | 2 | 3 |
| Investments | 0 | 0 | 0 | 0 | 39 | 0 |
| Other assets | 185 | 278 | 376 | 491 | 563 | 624 |
| Total assets | 462 | 555 | 723 | 852 | 954 | 991 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | 27 | 94 | 144 | 200 | 157 | 167 |
| Cash from investing | -19 | -74 | -108 | -158 | -111 | -178 |
| Cash from financing | -3 | -3 | -26 | -32 | -46 | -46 |
| Net cash flow | 5 | 17 | 11 | 9 | 0 | -57 |
| Free cash flow | 6 | 65 | 100 | 131 | 120 | 108 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 40 | 18 | 23 | 17 | 20 | 28 |
| Cash conversion cycle | 40 | 18 | 23 | 17 | 20 | 28 |
| Working capital days | -1 | -2 | -12 | -24 | -19 | -4 |
| Return on capital employed | 3.0% | 29.0% | 34.0% | 38.0% | 39.0% | 36.0% |
| Dividend payout | 0.0% | 39.0% | 32.0% | 33.0% | 26.0% | 20.0% |
What the price assumes
AttractiveTo justify its price of ₹312, this stock must grow earnings at 8% every year for 7 years. Our analysis caps realistic growth at ~29%. At that growth it is worth ₹889 — upside of 185%.
- Growth the price implies
- 8.5% a year
- for 7 years, fading to 4%
- It has actually compounded at
- 28.6% a year
- net profit, FY23–FY26 · EPS 28.7%
- The gap
- -0.2 pp
- 185% downside if it only repeats history
Ownership
Who owns it
Promoters hold 51.00% as of Sept 2026; institutions added 0.80 pts since Jun 2026.
- Promoters 51.00%
- Foreign institutions 2.39%
- Domestic institutions 1.77%
- Public 44.83%
Who bought this quarter
since Jun 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- newly disclosed 1.07% held
The same filing shows 0 holders trimming and 2 off the list — both are in the register beside this.
Who is on the register
Named in the Sep 2026 filing
Every holder of Indraprastha Medical Corporation Limited above SEBI's 1% disclosure line, and what changed since Jun 2026.
| Holder | Stake | Change |
|---|---|---|
| 26.00% | unchanged | |
| 22.02% | unchanged | |
| 1.70% | unchanged | |
| 1.61% | unchanged | |
| 1.29% | unchanged | |
| 1.07% | newly disclosed | |
| 0.42% | unchanged | |
| 0.26% | unchanged | |
| 0.22% | unchanged | |
| 0.18% | unchanged | |
| 0.15% | unchanged | |
| 0.13% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for Indraprastha Medical Corporation Limited
Free account: one company. Everything above stays public.
Write why you follow Indraprastha Medical Corporation Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Healthcare companies
- SH
SHUKRAPHARShukra Pharmaceuticals Limited - SO
SOLARASolara Active Pharma Sciences Limited - IN
INDSWFTLABInd-Swift Laboratories Limited - AD
ADVENZYMESAdvanced Enzyme Technologies Limited - DR
DRAGARWQDr Agarwals Eye Hospital Limited - HI
HIKALHikal Limited - FR
FREDUNFredun Pharmaceuticals Limited - KM
KMCSHILKMC Speciality Hospitals India Limited
Learn to analyse Indraprastha Medical Corporation Limited
Guides on how to read this kind of business and the numbers that matter.